Division of Urology, Southern Illinois University School of Medicine, Springfield, Illinois.
Urological Institution of Northeastern New York, Albany, New York.
J Urol. 2017 May;197(5):1326-1331. doi: 10.1016/j.juro.2017.01.018. Epub 2017 Jan 10.
We sought to determine the role of sex hormone-binding globulin in patients with male infertility.
We retrospectively reviewed the records of 168 males seen at a fertility clinic from 2012 to 2014 to investigate the accuracy of total testosterone in the biochemical diagnosis of hypogonadism using calculated bioavailable testosterone as the reference value. We used multivariable analysis to assess sex hormone-binding globulin as an independent predictor of infertility.
Computations using calculated bioavailable testosterone as a standard in the measurement of definitive biochemical hypogonadism (less than 156 ng/dl) revealed 81% sensitivity, 83% specificity, 81% positive predictive value and 82% negative predictive value for diagnosing hypogonadism with total testosterone alone. Of the 90 men with total testosterone greater than 300 ng/dl, 20% had low bioavailable testosterone less than 156 ng/dl, 52% had borderline low bioavailable testosterone less than 210 ng/dl and only 48% could be considered biochemically eugonadal according to calculated bioavailable testosterone. Of the 80 patients with total testosterone less than 300 ng/dl, 19% had free testosterone levels greater than 6.5 ng/dl and, thus, could be considered to be eugonadal. By a magnitude similar to that of follicle-stimulating hormone, sex hormone-binding globulin independently predicted decreased sperm concentration (p = 0.0027) and motility (p = 0.0447). After excluding men with azoospermia, only sex hormone-binding globulin levels differed significantly in classically hypogonadal men (group 1-total testosterone less than 300 ng/dl) and those missed but hypogonadal (group 2-calculated bioavailable testosterone less than 210 ng/dl) (p = 0.0001). At a more stringent cutoff of calculated bioavailable testosterone less than 156 ng/dl, sperm motility was significantly different for groups 1 and 2 (p = 0.014).
Adding sex hormone-binding globulin to total testosterone serum testing facilitates more accurate diagnosis with free testosterone and calculated bioavailable testosterone, and clinical implications of decreased semen parameters to a magnitude similar to that of follicle-stimulating hormone. This warrants further study of the role of sex hormone-binding globulin in male infertility.
我们旨在探讨性激素结合球蛋白在男性不育症患者中的作用。
我们回顾性分析了 2012 年至 2014 年在一家生育诊所就诊的 168 名男性的病历,以调查使用计算得出的生物可利用睾酮作为参考值时总睾酮在诊断性腺功能减退症的生化检测中的准确性。我们采用多变量分析评估性激素结合球蛋白作为不育症的独立预测因子。
使用计算得出的生物可利用睾酮作为标准测量明确的生化性腺功能减退症(低于 156ng/dl)时,总睾酮的检测具有 81%的敏感性、83%的特异性、81%的阳性预测值和 82%的阴性预测值。在总睾酮大于 300ng/dl 的 90 名男性中,20%的人生物可利用睾酮低(低于 156ng/dl),52%的人生物可利用睾酮低(低于 210ng/dl),仅 48%的人根据计算得出的生物可利用睾酮可被认为是生化正常的。在总睾酮小于 300ng/dl 的 80 名患者中,19%的人游离睾酮水平大于 6.5ng/dl,因此可被认为是正常的。与卵泡刺激素的程度相似,性激素结合球蛋白独立预测精子浓度降低(p=0.0027)和活力降低(p=0.0447)。排除无精子症患者后,仅在经典性腺功能减退症患者(组 1-总睾酮低于 300ng/dl)和漏诊但性腺功能减退症患者(组 2-计算得出的生物可利用睾酮低于 210ng/dl)中,性激素结合球蛋白水平有显著差异(p=0.0001)。在更严格的计算得出的生物可利用睾酮低于 156ng/dl 的截止值下,组 1 和组 2 的精子活力有显著差异(p=0.014)。
在总睾酮血清检测中加入性激素结合球蛋白可通过游离睾酮和计算得出的生物可利用睾酮更准确地诊断,并具有与卵泡刺激素相似程度的精液参数降低的临床意义。这需要进一步研究性激素结合球蛋白在男性不育症中的作用。